SARS-CoV-2 Tests available (not available for US-citizens)
The emerging Coronavirus (SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus 2) led to an outbreak of the respiratory disease «COVID-19» (coronavirus disease 19) in Wuhan, China, in December 2019. Similar to previous outbreaks of human coronavirus infection, SARS-CoV in 2003[1],[2] and MERS-CoV in 2012 [3], the new SARS-CoV-2 infection causes clinical symptoms such as fever, dry cough, myalgia and/or fatigue. Some patients may suffer from pain or symptoms like a stuffy or runny nose, sore throat, loss of smell (anosmia)/taste (ageusia) or diarrhoea. COVID-19 developed into a pandemic that spread rapidly in China and later worldwide.
The emerging Coronavirus (SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus 2) led to an outbreak of the respiratory disease «COVID-19» (coronavirus disease 19) in Wuhan, China, in December 2019. Similar to previous outbreaks of human coronavirus infection, SARS-CoV in 2003[1],[2] and MERS-CoV in 2012 [3], the new SARS-CoV-2 infection causes clinical symptoms such as fever, dry cough, myalgia and/or fatigue. Some patients may suffer from pain or symptoms like a stuffy or runny nose, sore throat, loss of smell (anosmia)/taste (ageusia) or diarrhoea. COVID-19 developed into a pandemic that spread rapidly in China and later worldwide.
The outbreak of this disease has forced state authorities to take drastic steps to contain the situation, including the quarantine of many millions of people across the world. However, these efforts are limited by a serious problem — the differentiation of those who are/have been infected with COVID-19 from those who do not have the infection. The clinical symptoms present in confirmed COVID-19 cases are not unique to COVID-19 since they are similar to those of other infectious viral diseases such as influenza [4]. The viral nucleic acid real-time polymerase chain reaction test is currently the standard tool for supporting clinical diagnosis of the infection [5] despite long turnaround times, the expensive equipment required and reports of false negative results for the COVID-19 RT-PCR [6].
To support efforts to contain the further spread there is an urgent need to use different test methods to swiftly identify and classify patients infected with SARS-CoV-2. This will help prevent further transmission of the virus and ensure early treatment of patients.
Literature:
[1] Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953-1966.
[2] Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263-270.
[3] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820
[4] Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58(8):1095-1103
[5] Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (COVID-19) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4
[6] Gallagher J. Are Coronavirus Tests Flawed? BBC News, www.bbccom/news/health-51491763. 13 Feb. 2020
Коронавирус: | ||||
---|---|---|---|---|
CD3-/CD57+/CD56+/CD45+ Cells | ArminLabs (DE) | CD3-/CD57+/CD56+/CD45+ Cells ∘ пробирка Hep.,EDTA | €116 | |
Immuneprofile (CD19/CD3-/CD57+/CD56+/CD45+ Cells) | ArminLabs (DE) | CD19/CD3-/CD57+/CD56+/CD45+ Cells ∘ The absolute cell counts and percentages of T lymphocytes, B lymphocytes, helper/inducer T lymphocytes and suppressor/cytotoxic T lymphocytes can be used to characterise and study some forms of immunodeficiencies and autoimmune diseases. ∘ CD3-CD57 helper/ inducer lymphocytes are a subpopulation of T lymphocytes (CD3). Determination of the percentage or absolute cell count of helper/inducer T lymphocytes can be useful in the investigation of chronic Lyme disease. | €160 | |
SARS-CoV-2 IgG-/IgA-antibodies | ArminLabs (DE) | SARS-CoV-2 IgG-/IgA-antibodies ∘ пробирка: Serum/Z-Gel | €54 | |
SARS-CoV-2 IgG-antibodies | ArminLabs (DE) | SARS-CoV-2 IgG-antibodies | €27 | |
SARS-CoV-2 iSpot (2 antigens) | ArminLabs (DE) | SARS-CoV-2 iSpot (2 antigens) ∘ пробирка 3 x ACD/CPDA | €265 | |
SARS-CoV-2 iSpot (SARS-Mix) | ArminLabs (DE) | Преимущества SARS-CoV-2 iSpot ∘ - Эффективное, непрямое выявление предшествующего заболевания COVID-19 ∘ - дифференцированное изображение иммунного ответа для демонстрации развития течения заболевания и иммунитета после перенесенной инфекции ∘ - современный метод клеточного тестирования для дифференциации инфекций гриппа и COVID-19 ∘ - очень вероятен базовый клеточный иммунитет - вопрос о базовом иммунитете через клеточную иммунную систему после предыдущего контакта с глобально эндемичными коронавирусами ∘ - если обнаружены специфические для SARS-CoV-2 клоны Т-клеток, это не только свидетельство предыдущего контакта с вирусом, но и может указывать на существующий клеточный иммунитет | €162 | |
Vitamin D3 (25OH) | ArminLabs (DE) | Витамин Д (25OH) ∘ пробирка SERUM | €38 | |
Zonulin | ArminLabs (DE) | зонулин в сыворотке ∘ пробирка: 1 x Serum/SST | €59 |
Complementary Test-Recommendations by ArminLabs
CD3+/CD56+/CD57+/CD45+ NK-Cells (Immune-Status), Zonulin and Vitamin D3.
Elderly people and patients with underlying medical conditions such as hypertension, cardiac issues or diabetes, cancer, another active infection and/or those suffering from immunosuppression are more likely to experience more severe symptoms of COVID-19 [1],[2],[3]
[1] Okba et al. medRxiv 2020.03.18.20038059; doi: 10.1101/2020.03.18.20038059; März 2020
[2] Risk of COVID-19 for patients with cancer; Hanping Wang, Li Zhang; Published:March 03, 2020
[3] The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer; Sarju Ganatra, MD, Sarah P. Hammond, MD, Anju Nohria, MD; 18 March 2020
ArminLabs therefore additionally recommend checking innate (CD3+) and natural killer cell (CD56+/CD57+) immune status, as well as other parameters related to current immune status:
Дополнительно: | ||||
---|---|---|---|---|
CD3-/CD57+/CD56+/CD45+ Cells | ArminLabs (DE) | CD3-/CD57+/CD56+/CD45+ Cells ∘ пробирка Hep.,EDTA | €116 | |
Vitamin D3 (25OH) | ArminLabs (DE) | Витамин Д (25OH) ∘ пробирка SERUM | €38 | |
Zonulin | ArminLabs (DE) | зонулин в сыворотке ∘ пробирка: 1 x Serum/SST | €59 | |
Immuneprofile (CD19/CD3-/CD57+/CD56+/CD45+ Cells) | ArminLabs (DE) | CD19/CD3-/CD57+/CD56+/CD45+ Cells ∘ The absolute cell counts and percentages of T lymphocytes, B lymphocytes, helper/inducer T lymphocytes and suppressor/cytotoxic T lymphocytes can be used to characterise and study some forms of immunodeficiencies and autoimmune diseases. ∘ CD3-CD57 helper/ inducer lymphocytes are a subpopulation of T lymphocytes (CD3). Determination of the percentage or absolute cell count of helper/inducer T lymphocytes can be useful in the investigation of chronic Lyme disease. | €160 |